Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Clinical Trial of NPC-06 in Patients With Neuropathic Pain in Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03773055
Recruitment Status : Recruiting
First Posted : December 12, 2018
Last Update Posted : August 4, 2020
Sponsor:
Information provided by (Responsible Party):
Nobelpharma

Brief Summary:
The purpose of this trial is to investigate the efficiency of pain relief and the safety of NPC-06 for the neuropathic pain associated with cancer, in addition to explore the effective concentration of NPC-06.

Condition or disease Intervention/treatment Phase
Neuropathic Pain in Cancer Drug: NPC-06 Phase 2

Detailed Description:
The eligible patients will be randomized into three groups, and will receive NPC-06 (high dose), NPC-06 (low dose) or placebo once a day for 7 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Group Trial to Investigate the Proof of Concept of NPC-06 in Patients With Neuropathic Pain in Cancer
Actual Study Start Date : April 3, 2019
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : September 30, 2020

Arm Intervention/treatment
Active Comparator: NPC-06 (High dosage)
18 mg (iv) in Day 1 as an induction dosage and 9 mg (iv) in Day 2 - 7 as a maintenance dosage
Drug: NPC-06
Patients will receive once a day for 7 days.

Active Comparator: NPC-06 (Low dosage)
15 mg (iv) in Day 1 as an induction dosage and 6 mg (iv) in Day 2 - 7 as a maintenance dosage
Drug: NPC-06
Patients will receive once a day for 7 days.

Placebo Comparator: Placebo
Saline will be administered intravenously
Drug: NPC-06
Patients will receive once a day for 7 days.




Primary Outcome Measures :
  1. Improvement of Numeric Rating Scale (NRS) score within 2 hours after administration [ Time Frame: Pre-administration, 30, 60, 90 and 120 minutes post-administration ]
    Average change (slope) of NRS score


Secondary Outcome Measures :
  1. Other improvements of NRS score [ Time Frame: Pre-dose, Days 1,2,3,4,5,6,7,8,9,10,11,12,13 ]
    Change of NRS score, Change of NRS score of persistent pain, Change of maximum pain, at the time of evaluation compared to baseline

  2. Time to event [ Time Frame: 2 hours after initial administration to Day 7 ]
    Time to event analysis of analgesic effect

  3. Improvement of Neuropathic Pain Symptom Inventory (NPSI) score [ Time Frame: Pre-dose, Days 1,2,3,4,5,6,7,8,9,10,11,12,13 ]
    Change of NPSI score compared to baseline

  4. Rescue medication use [ Time Frame: Day 1 to Day 13 ]
    Number of times of rescue medication use

  5. Effective concentration [ Time Frame: Day 0 to Day 13 ]
    Blood phenytoin concentration



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 16 years old or greater at the time of informed consent
  2. Both genders
  3. Patients who can admit to hospital for all assessment duration from first administration until the next day of final administration. (including the hospitalized patient )
  4. Patients who are diagnosed and informed as cancer (including sarcoma, lymphoma and multiple myeloma)
  5. Patients who are diagnosed as neuropathic pain by neurological examination and imaging findings
  6. Patients who NRS score of average persistent pain is higher than 4, even they were treated with level 3 of WHO three-step analgesic ladder at the observation period.
  7. Patients who NRS score at the time of first administration and NRS score of persistent pain in the past 24 hours are higher than 4.
  8. Patients who average number of daily rescue medication use during observation period is less than 6.
  9. Patients who are predicted to survive longer than 3 month.
  10. Patients who ECOG Performance Status (PS) score is 0 to 3.
  11. Patients who (or whose legally acceptable representative if the patient is underage) provide a written consent at their own will with a full understanding after receiving a sufficient explanation on participation in the study

Exclusion Criteria:

  1. Patients who can not evaluate NRS by themselves.
  2. Patients who have leukemia as a complication.
  3. Patients who have a primary brain neoplasm or a metastatic brain neoplasm as a complication.
  4. Patients who have epilepsy, serious psychiatric or neurological disease ( i. e. dementia, Parkinson disease or schizophrenic disorder) or consciousness disturbance as a complication.
  5. Patients who have primary trigeminal neuralgia, diabetic neuropathy, post herpetic neuralgia or acute herpes zoster pain as a complication.
  6. Patients who has other serious pain which affect the evaluation of neuropathic pain in cancer.
  7. Patients who have sinus bradycardia or serious disturbance of conduction system.
  8. Patients who have history of hypersensitivity against hydantoin compound.
  9. Patients who are administrated tadalafil (for pulmonary hypertension), rilpivirine, asunaprevir, daclatasvir, vaniprevir, macitentan or sofosbuvir.
  10. Patients who are administrated methadone.
  11. Patients who have complications such as serious heart disease, hepatic function disorder or renal function disorder which severity are considered by investigator as grade 3 or more severe with reference to ''Concerning classification criteria for seriousness of adverse drug reactions of medical agents'' (except cancer).
  12. Patients who received surgical treatment or internal radiation therapy in past three month before the first day of pre observation period.
  13. Patients who are treated nerve block, radiation therapy, spinal cord stimulation or surgical treatment for the part of neuropathic pain in past one month before the first day of pre observation period.
  14. Patients who change the usage or dosage of medication for cancer as primal disease in the past two week before the first day of the pre observation period, or patients who are predicted not to continue the treatment without change in the medication while this clinical trial.
  15. Patients who are administrating with fosphenytoin, phenytoin or ethotoin or have taken these drugs as medication for neuropathic pain.
  16. Patients who have participated in other clinical trial and have taken a trial drug in past three month before the first day of pre observation period.
  17. Female patients who are pregnant or lactating or who may be pregnancy in the period of the clinical trial.
  18. Patients who can not agree to prevent contraception appropriately following the direction of the Investigator or the sub-investigator.
  19. Any other patients who are considered by the investigator as unsuitable for participation in the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03773055


Contacts
Layout table for location contacts
Contact: Kenji Shimizu +81-3-5651-1177 shimizu@nobelpharma.co.jp
Contact: Saori Arai +81-3-5651-1177 arai@nobelpharma.co.jp

Locations
Layout table for location information
Japan
Keio Hospital Recruiting
Shinjuku-Ku, Tokyo, Japan, 160-8582
Contact: Saori Hashiguchi         
Sponsors and Collaborators
Nobelpharma
Layout table for additonal information
Responsible Party: Nobelpharma
ClinicalTrials.gov Identifier: NCT03773055    
Other Study ID Numbers: NPC-06-4
First Posted: December 12, 2018    Key Record Dates
Last Update Posted: August 4, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuralgia
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Pain
Neurologic Manifestations